JP2003523721A - 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 - Google Patents

抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用

Info

Publication number
JP2003523721A
JP2003523721A JP2000591195A JP2000591195A JP2003523721A JP 2003523721 A JP2003523721 A JP 2003523721A JP 2000591195 A JP2000591195 A JP 2000591195A JP 2000591195 A JP2000591195 A JP 2000591195A JP 2003523721 A JP2003523721 A JP 2003523721A
Authority
JP
Japan
Prior art keywords
polypeptide
expression cassette
nucleotides
polynucleotide sequence
gag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000591195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003523721A5 (https=
Inventor
スーザン バーネット,
ジャン ザーメジェド,
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2003523721A publication Critical patent/JP2003523721A/ja
Publication of JP2003523721A5 publication Critical patent/JP2003523721A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16051Methods of production or purification of viral material
    • C12N2740/16052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2000591195A 1998-12-31 1999-12-30 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 Pending JP2003523721A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11449598P 1998-12-31 1998-12-31
US60/114,495 1998-12-31
US15219599P 1999-09-01 1999-09-01
US60/152,195 1999-09-01
PCT/US1999/031273 WO2000039304A2 (en) 1998-12-31 1999-12-30 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2003523721A true JP2003523721A (ja) 2003-08-12
JP2003523721A5 JP2003523721A5 (https=) 2007-03-01

Family

ID=26812259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000591195A Pending JP2003523721A (ja) 1998-12-31 1999-12-30 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用

Country Status (6)

Country Link
US (2) US7943375B2 (https=)
EP (1) EP1141314A2 (https=)
JP (1) JP2003523721A (https=)
AU (1) AU2487300A (https=)
CA (1) CA2358385C (https=)
WO (1) WO2000039304A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014156477A (ja) * 2007-02-01 2014-08-28 Tcf Gmbh 調節性t細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
BR0010077A (pt) * 1999-04-26 2002-01-15 K U Leuven Res & Dev Universit Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas
AP1674A (en) 1999-11-16 2006-10-30 Geneart Ag The genome of the HIV-1 inter-subtype (C/B') and use thereof.
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
AU784679B2 (en) * 1999-12-23 2006-05-25 International Aids Vaccine Initiative Improvements in or relating to immune responses to HIV
DE60026199T2 (de) 2000-05-18 2006-11-23 Geneart Ag Synthetische Gene für gagpol und deren Verwendungen
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
CA2434546C (en) * 2001-01-12 2012-09-11 Chiron Corporation Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
CA2492823A1 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2501476A1 (en) 2002-10-07 2004-04-22 Chiron Corporation Hiv vaccine formulations
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
CN101072585A (zh) 2004-11-01 2007-11-14 诺华疫苗和诊断公司 产生免疫应答的组合方法
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2636139A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
US20130052221A1 (en) * 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
CN104271155A (zh) 2011-11-14 2015-01-07 诺华股份有限公司 聚阴离子卡波姆和Env多肽的免疫原性复合物及其制造方法和用途
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034640A2 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602705A (en) 1981-11-09 1986-07-29 Lucas Industries Public Limited Company Flywheel mechanism for anti-skid braking systems
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US6858712B1 (en) * 1984-08-22 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US5032510A (en) * 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
EP0203177A4 (en) 1984-11-29 1987-04-28 Scripps Clinic Res POLYPEPTIDES AND ANTIBODIES ASSOCIATED WITH VIRAL GLUCOPROTEINS WITHOUT GLUCOSE.
DE3588134T2 (de) 1984-12-24 1997-03-20 Genentech Inc Fusionen von AIDS-verwandten Polypeptiden
FI861626A7 (fi) 1985-04-19 1986-10-20 Hoffmann La Roche Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids.
ATE108022T1 (de) 1985-10-24 1994-07-15 Southwest Found Biomed Res Synthetische peptide und deren verwendung zur diagnose und impfung für aids und arc.
EP0242216A1 (en) 1986-04-16 1987-10-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III
JPH01500432A (ja) 1986-07-21 1989-02-16 サウスウェスト・ファウンデーション・フォー・バイオメディカル・リサーチ Aidsおよびarcのウィルス原因物質に対して免疫化するための組成物および方法
US4861707A (en) * 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
EP0300213A1 (en) 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Hepatitis a viral peptide particle immunogens
US5637677A (en) * 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
WO1989002277A2 (en) 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
JPH02501192A (ja) 1987-09-04 1990-04-26 バイオジェン インコーポレイテッド 可溶性t4蛋白を製造するためのdna配列、組換dna分子および方法
US5879907A (en) * 1987-09-14 1999-03-09 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof and method
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
CA1340748C (en) 1988-07-13 1999-09-14 Stephen Oroszlan Synthetic hiv protease gene and method for its expression
ATE112687T1 (de) * 1988-09-13 1994-10-15 Chiron Corp Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
AU640619B2 (en) 1988-10-03 1993-09-02 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
US5858646A (en) * 1989-02-23 1999-01-12 University Of Ottawa Modified HIV-pol polypeptide having immunological activity for use as diagnostic reagent
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL93682A (en) 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
WO1990011359A1 (en) 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
AU5421090A (en) 1989-04-05 1990-11-05 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A clone of double-stranded rna virus and applications thereof
JP3034025B2 (ja) 1989-06-01 2000-04-17 アプライド・バイオテクノロジー・インコーポレーテツド 自己アセンブルド欠損非自己増殖性ウイルス粒子
US5130247A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
AU6523590A (en) 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
EP0424748B1 (en) * 1989-10-23 1995-05-10 F. Hoffmann-La Roche Ag Synthetic envelope peptides of HTLV-I
WO1991006319A1 (en) 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
WO1991007510A1 (en) 1989-11-17 1991-05-30 Amgen Inc. A method of detecting htlv-i antibodies in human body fluids
EP0502105A4 (en) 1989-11-20 1993-02-24 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
CA2077753C (en) 1990-03-09 2000-02-29 Nancy L. Haigwood Purified gp120 composition retaining natural conformation
US5876724A (en) * 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
ATE183235T1 (de) 1990-03-21 1999-08-15 Wolf Hans Joachim Prof Dr Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
JP3494300B2 (ja) 1990-04-03 2004-02-09 ジェネンテック・インコーポレーテッド Hivに対する予防接種のための方法および組成物
WO1991015512A2 (en) 1990-04-03 1991-10-17 Genentech, Inc. Hiv envelope polypeptides
IL97985A0 (en) 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
AU641554B2 (en) 1990-08-29 1993-09-23 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Novel peptide antigens and immunoassays, test kits and vaccines using the same
US5840313A (en) * 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0550516A1 (en) 1990-09-28 1993-07-14 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
PT100090A (pt) * 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
CA2104958A1 (en) * 1991-03-07 1992-09-08 Jean C. Nichols Use of cell surface receptor targeted molecules for the treatment of viral diseases
US6139843A (en) * 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
WO1993002102A1 (en) 1991-07-23 1993-02-04 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Novel peptide antigens and immunoassays, test kits and vaccines using the same
WO1993004090A1 (en) 1991-08-22 1993-03-04 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
US5665569A (en) * 1991-08-22 1997-09-09 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
RU2212899C2 (ru) * 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
WO1993008836A1 (en) 1991-10-28 1993-05-13 Institut Pasteur Induction of protection against viral infection by synergy between viral proteins and viral peptides
WO1993014789A1 (en) 1992-01-22 1993-08-05 New England Medical Center Hospitals, Inc. Pathogen-specific ctl therapy
US5174666A (en) 1992-02-12 1992-12-29 Smith Corona Corporation Printing device having printwheel coupling means
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
JP2001504572A (ja) 1992-04-09 2001-04-03 アボツト・ラボラトリーズ Hiv抗原及びhiv抗体を検出するためのアッセイ
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US5686078A (en) * 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
FI951488L (fi) 1992-09-30 1995-05-23 Scripps Research Inst Ihmisen immuunikatoviruksen vastaiset ihmisen neutraloivat monoklonaaliset vasta-aineet
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5304472A (en) * 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
ES2156149T3 (es) * 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
WO1994016060A1 (en) 1993-01-11 1994-07-21 The Trustees Of The University Of Pennsylvania Mutants of hiv for supression of hiv infection
AU692433B2 (en) 1993-01-13 1998-06-11 Arsinur Burcoglu Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
WO1994016081A1 (de) * 1993-01-16 1994-07-21 Manfred Schawaller Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
HU219767B (hu) 1993-01-26 2001-07-30 Leslie R. Coney Készítmények és eljárások genetikai anyag sejtbe történő beviteléhez
US6955900B1 (en) 1993-02-02 2005-10-18 The Scripps Research Institute Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
WO1994020640A1 (en) 1993-03-05 1994-09-15 Genelabs Technologies, Inc. Method for hiv quantitation
CA2157900A1 (en) 1993-03-11 1994-09-15 Angeline Douvas Therapeutic strategies for immunoinfective cluster virus infections
US5869624A (en) 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
KR100325554B1 (ko) 1993-03-26 2002-11-02 젠-프로브 인코포레이티드 사람의면역결핍 바이러스타입1의검출
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
WO1994028929A1 (en) * 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
CN1111540C (zh) 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv-1肽类
US5614413A (en) * 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
CA2125344A1 (en) * 1993-07-01 1995-01-02 Casey D. Morrow Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
AU688364B2 (en) 1993-07-19 1998-03-12 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
WO1995004818A1 (en) 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
WO1995011317A1 (en) 1993-10-19 1995-04-27 The Scripps Research Institute Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2169453A1 (en) 1993-10-26 1995-05-04 Cecil Czerkinsky Inhibition of hiv mucosal infection
IL112820A0 (en) 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
CA2185129A1 (en) 1994-03-14 1995-09-21 Angeline Douvas Methods to diagnose and treat hiv-1 infection
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
ATE221786T1 (de) 1994-04-29 2002-08-15 Univ Duke Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
JPH10502165A (ja) 1994-05-31 1998-02-24 アボツト・ラボラトリーズ 合成ペプチド−改良イムノアッセイを使用する異なるhiv遺伝子型の検出
US6355247B1 (en) 1994-06-02 2002-03-12 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
US5733781A (en) 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6291157B1 (en) * 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
AU3593095A (en) 1994-09-23 1996-04-09 Johns Hopkins University School Of Medicine, The Method of treatment of human immunodeficiency virus (hiv) infection
WO1996016178A1 (en) 1994-11-17 1996-05-30 Maxim Pharmaceuticals, Inc. Immunogens for stimulating mucosal immunity
US5550280A (en) * 1994-11-30 1996-08-27 Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee Hindered aromatic ester compounds useful as anti-viral agents
JPH10512243A (ja) 1994-12-30 1998-11-24 カイロン コーポレイション 遺伝子送達ビヒクルの非外傷性投与
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
FR2730411B1 (fr) 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
WO1997003198A2 (en) 1995-07-07 1997-01-30 Texas A & M University System Nucleotide and amino acid sequence and uses thereof
TR199800573T2 (xx) 1995-09-28 1998-07-21 University Of Pittsburgh-Commonwealth System Of Higher Edu. Hedeflenen partik�lat genetik immunizasyonu sureti ile h�cre medyasyonlu immun cevaplar�n stim�lasyonu.
WO1997026009A1 (en) 1996-01-17 1997-07-24 Progenics Pharmaceuticals, Inc. Compounds capable of inhibiting hiv-1 infection
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6087486A (en) 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
US6060587A (en) * 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
US5649652A (en) 1996-02-16 1997-07-22 Sackett; Eleanor L. Clothes hanger with storage hook
PL328730A1 (en) * 1996-02-22 1999-02-15 Merck & Co Inc Synthetic hiv genes
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2258568A1 (en) 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
US5951975A (en) * 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
AU4088697A (en) 1996-08-26 1998-03-19 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
WO1998010069A2 (en) * 1996-09-06 1998-03-12 The Regents Of The University Of California E25a PROTEIN, METHODS FOR PRODUCTION AND USE THEREOF
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6139833A (en) * 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US5830697A (en) * 1997-01-21 1998-11-03 The Board Of Trustees Of The Leland Stanford Junior University P-glycoprotein mutant resistant to cyclosporin modulation
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
WO1998041536A1 (en) 1997-03-14 1998-09-24 President And Fellows Of Harvard College Glycosylation deficient siv and hiv envelope glycoproteins
AU737155B2 (en) 1997-03-14 2001-08-09 Biogen Idec Inc. Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
IL131843A (en) 1997-03-24 2004-06-20 Univ Kingston A method for detecting coincidences, products and devices
AU754242B2 (en) 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5858675A (en) * 1997-05-13 1999-01-12 Incyte Pharmaceuticals, Inc. Double-stranded RNA-binding protein
US6099847A (en) * 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
WO1998059074A1 (en) 1997-06-23 1998-12-30 Emory University Human immunodeficiency viruses causing aids in a nonhuman primate
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
EP1000177B1 (en) 1997-08-01 2007-04-25 Genetic Systems Corporation Synthetic antigens for the detection of antibodies having immunoreactivity against hiv virus
WO1999012416A1 (en) 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
CA2302275C (en) 1997-09-19 2009-12-08 Shire Laboratories, Inc. Solid solution beadlet
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US5932445A (en) * 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
JP2003521221A (ja) 1998-02-11 2003-07-15 ジェンベク、インコーポレイティッド 有害ウイルス真核生物遺伝子導入ベクターの製造の為のベクター、細胞および方法
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
WO1999053046A2 (en) * 1998-04-14 1999-10-21 Chiron Corporation Noncloning technique for expressing a gene of interest
AU3489499A (en) 1998-04-14 1999-11-01 Merck & Co., Inc. Needleless administration of polynucleotide formulations
JP2002512013A (ja) 1998-04-22 2002-04-23 カイロン コーポレイション ケモカインを使用することによる遺伝的免疫に対する免疫応答の増強
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
FR2780069B1 (fr) 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
CN1321165A (zh) 1998-08-03 2001-11-07 蒙他拿州大学 病毒性疾病的预防和治疗
WO2000015819A1 (en) * 1998-09-11 2000-03-23 The Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
WO2000018929A2 (en) 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
AU6425999A (en) 1998-10-09 2000-05-01 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6489542B1 (en) * 1998-11-04 2002-12-03 Monsanto Technology Llc Methods for transforming plants to express Cry2Ab δ-endotoxins targeted to the plastids
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 改変hivenvポリペプチド
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
DE60042396D1 (de) 1999-01-27 2009-07-30 Carstens Carsten Peter Hohe expression eines heterologen proteins mit seltenen codons
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
BR0010077A (pt) 1999-04-26 2002-01-15 K U Leuven Res & Dev Universit Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas
MXPA01011137A (es) 1999-05-03 2003-07-14 Uab Research Foundation Inmunizacion genetica no invasiva, productos de la expresion a partir de esta, y sus usos.
CN100352921C (zh) 1999-05-06 2007-12-05 威克福雷大学 用于鉴定引起免疫反应的抗原的组合物和方法
WO2000067787A2 (en) 1999-05-06 2000-11-16 The Immune Response Corporation Hiv immunogenic compositions and methods
US6420545B1 (en) 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US6280989B1 (en) * 1999-06-17 2001-08-28 Dmitri Kapitonov Sialyltransferases
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
ATE419869T1 (de) 1999-08-19 2009-01-15 Dynavax Tech Corp Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
CA2392010A1 (en) 1999-08-27 2001-03-08 Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
EP1214333A4 (en) 1999-09-17 2005-01-19 Dana Farber Cancer Inst Inc SOLUBLE STABILIZED GLYCOPROTEIN TRIMERS
CA2384828A1 (en) 1999-09-21 2001-03-29 Zivko Nikolov Methods for producing recombinant proteins
PT1221968E (pt) 1999-10-13 2010-04-16 Novartis Vaccines & Diagnostic Processo de obtenção de respostas imunes celulares de proteínas
WO2001029225A1 (en) 1999-10-21 2001-04-26 Panorama Research, Inc. A general method for optimizing the expression of heterologous proteins
US6316253B1 (en) * 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
AU782880B2 (en) 1999-11-13 2005-09-08 Merck Patent Gmbh High order nucleic acid based structures
AU2841101A (en) 1999-12-08 2001-06-18 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
CA2393861A1 (en) 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
WO2001045748A1 (en) 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
CA2395269C (en) 1999-12-23 2015-12-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
AU784679B2 (en) 1999-12-23 2006-05-25 International Aids Vaccine Initiative Improvements in or relating to immune responses to HIV
BR0107972A (pt) 2000-01-31 2002-11-05 Smithkline Beecham Biologicals Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
WO2001054701A1 (en) 2000-01-31 2001-08-02 Aventis Pasteur, S.A. Vaccination of hiv infected persons following highly active antiretroviral therapy
AU2001238501A1 (en) 2000-02-16 2001-08-27 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
EP1274305A4 (en) 2000-02-18 2004-04-14 Univ Washington AID OF THE AIDS VIRUS AND VACCINE
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034640A2 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6009041335; J. Virol., 1997年, vol. 71, no. 7, p. 4892-4903 *
JPN6009041338; J. Virol., 1998年, vol. 72, no. 2, p. 1497-1503 *
JPN6013038516; Journal of Virology Vol.73,No.5, 1999, p.4427-4432

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014156477A (ja) * 2007-02-01 2014-08-28 Tcf Gmbh 調節性t細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用

Also Published As

Publication number Publication date
US7943375B2 (en) 2011-05-17
US8541230B2 (en) 2013-09-24
WO2000039304A3 (en) 2001-01-18
AU2487300A (en) 2000-07-31
EP1141314A2 (en) 2001-10-10
CA2358385C (en) 2013-08-06
US20090047339A1 (en) 2009-02-19
US20110236469A1 (en) 2011-09-29
CA2358385A1 (en) 2000-07-06
WO2000039304A9 (en) 2000-12-07
WO2000039304A2 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
JP5033303B2 (ja) 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
US8541230B2 (en) Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1339738B1 (en) Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP2011172593A (ja) Hivポリペプチドの改善された発現およびウイルス様粒子の生成
JP2009082136A (ja) 抗原性b型hivポリペプチドおよび/または抗原性c型hivポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
US20080095833A1 (en) Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides, and uses thereof
JP2013146270A (ja) 抗原性b型hivポリペプチドをコードするポリヌクレオチド、そのポリペプチドおよびそれらの使用
EP1535995A1 (en) Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
HK1156662A (en) Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101014

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101027

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120827